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Abstract
Background: The inflammatory bowel diseases (IBD) Crohn’s disease and ulcerative colitis result from alterations in
intestinal microbes and the immune system. However, the precise dysfunctions of microbial metabolism in the
gastrointestinal microbiome during IBD remain unclear. We analyzed the microbiota of intestinal biopsies and stool
samples from 231 IBD and healthy subjects by 16S gene pyrosequencing and followed up a subset using shotgun
metagenomics. Gene and pathway composition were assessed, based on 16S data from phylogenetically-related
reference genomes, and associated using sparse multivariate linear modeling with medications, environmental
factors, and IBD status.
Results: Firmicutes and Enterobacteriaceae abundances were associated with disease status as expected, but also
with treatment and subject characteristics. Microbial function, though, was more consistently perturbed than
composition, with 12% of analyzed pathways changed compared with 2% of genera. We identified major shifts in
oxidative stress pathways, as well as decreased carbohydrate metabolism and amino acid biosynthesis in favor of
nutrient transport and uptake. The microbiome of ileal Crohn’s disease was notable for increases in virulence and
secretion pathways.
Conclusions: This inferred functional metagenomic information provides the first insights into community-wide
microbial processes and pathways that underpin IBD pathogenesis.
Background
Inflammatory bowel disease (IBD), a chronic and relapsing
inflammatory condition of the gastrointestinal (GI) tract,
is intimately linked to the microbial communities of the
human gut. Although it is now widely accepted that IBD
results from altered interactions between gut microbes
and the intestinal immune system, the precise nature of
the intestinal microbiota dysfunction in IBD remains to be
elucidated [1]. IBD further includes two main subtypes,
ulcerative colitis (UC) and Crohn’s disease (CD), which
each include distinct microbial perturbations and tissue
localizations. The former is confined to the colon, while
the latter may affect any part of the digestive tract, with
unclear implications for microbial involvement or causality
[2]. In particular, the microbial mechanisms and metabo-
lism underlying the role of the GI microbiome in IBD
onset and its alteration in the course of active treatment
and recovery are still unknown.
In the last decade, advances in DNA sequencing have
allowed exploration of the 40% of the gut microbiome
that is still uncultured [3], setting the stage for investiga-
tion of the IBD microbiome. The GI microbiome of
healthy humans is dominated by four major bacterial
phyla: Firmicutes, Bacteroidetes, and to a lesser degree
Proteobacteria and Actinobacteria [4,5]. Many studies
have observed imbalances or dysbioses in the GI micro-
biomes of IBD patients [6-13]; in both CD and UC
patients, there is decreased biodiversity, a lower propor-
tion of Firmicutes, and an increase in Gammaproteobac-
teria [14]. In CD, proportions of the Clostridia are
altered: the Roseburia and Faecalibacterium genera of
the Lachnospiracae and Ruminococcaceae families are
decreased, whereas Ruminococcus gnavus increases
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any medium, provided the original work is properly cited.[15-17]. Specific features of UC-associated dysbiosis are
less described, although increased sulfate-reducing Delta-
proteobacteria have been reported [18,19]. These studies
have described typical changes in composition of the
IBD gut community, but the functional roles of these
organisms - or of the entirety of a dysbiotic community -
remain less clear.
The normal gut microbiome exhibits tremendous func-
tional diversity encoded by a collection of bacterial genes
numbering more than 100 times the human gene set
[4,20]. Thus, the genomic potential of the human micro-
biome is far greater than that of its host, and treatments,
diets, or medications that affect the host will also likely
affect the microbiome. A primary example of the impor-
tance of the microbiome to host health is in the digestion
of dietary fiber, which is used by the microbiota of the
lower GI tract as their main source of energy [21]. Fibroly-
tic bacteria degrade polysaccharides into smaller carbohy-
drates, which are then fermented into short-chain fatty
acids (SCFAs) such as acetate, propionate, and butyrate.
Butyrate in particular is a major source of energy for colo-
nocytes, but all three of these have demonstrated immu-
nomodulatory properties [22-27]. In addition to these
metabolic functions, many genetic studies in IBD have
highlighted the central role of host-microbe interactions in
IBD pathogenesis [1,28-30]. Specific host pathways linked
to microbial response in IBD include T-cell activation, the
IL-23/T helper 17 pathway, autophagy [31], and Paneth
cell function [32]. Together, these results support the cen-
trality of host-microbiota crosstalk for gut homeostasis
and in turn the role of dysfunctional crosstalk between the
host and GI microbiome in IBD.
Little work has yet bridged the gap between IBD patho-
genesis in a human host, individual microbes, and altera-
tions in metabolism of the GI microbial community in
IBD. Few studies of the IBD gut microbiome have investi-
gated microbiome function [33], and these have not sys-
tematically accounted for the influences of treatments
and environmental factors. We have thus analyzed the GI
microbiomes of 121 CD patients, 75 UC patients, and 27
healthy controls using a novel multivariate metagenomic
analysis pipeline specifically accounting for environmen-
tal factors (including treatment, age, and tobacco use). In
addition to assessing microbiome composition, we have
analyzed the inferred metagenome as determined from
phylogenetically-associated reference genomes, including
metabolic modules and pathways also associated with
disease status and with environmental factors such as
medications and smoking. Not only were these GI micro-
biomes characterized by shifts in bacterial populations
during disease as previously described, but these
dysbioses were highly functionally coordinated. Cross-
species enrichments included mucin metabolism and
redox tolerance by means of glutathione transport,
cysteine biosynthesis, and riboflavin metabolism. Conver-
sely, processes linked broadly to clades IV and XIVa
Clostridia were depleted, particularly short chain fatty
acid production. Dysbioses inI B Da r ec o r r e s p o n d i n g l y
not simply structural changes in the gut microbiota, but
are instead associated with major impairments in many
fundamental microbial metabolic functions with potential
impact on the host.
Results
In order to measure compositional and functional differ-
ences between the gut microbiota of healthy and IBD-
affected individuals, 231 fecal and biopsy samples were
collected from the Ocean State Crohn’sa n dC o l i t i sA r e a
Registry (OSCCAR) and the Prospective Registry in IBD
Study at MGH (PRISM) database. OSCCAR is a state-
based, prospective inception IBD cohort, and PRISM is a
referral center-based, prospective IBD cohort (see Materi-
als and methods). The samples comprised 136 fecal speci-
mens and 95 colon or small intestinal biopsies, originating
from a cross-section of 121 CD patients, 75 UC patients,
27 healthy controls, and 8 indeterminate (Table 1).
In addition to general information such as gender and age,
data regarding disease characteristics (topography, disease
activity as measured by the Harvey-Bradshaw Index (HBI)
and the Simple Colitis Activity Index), treatment (antibio-
tics, corticosteroids, mesalamine, immunosuppressant),
and environmental exposure (tobacco use) were collected
from each subject and analyzed. DNA was extracted from
fecal samples and biopsies, and the 16S rRNA gene was
amplified and sequenced using 454 technology. The result-
ing sequences were then processed using a specific in silico
pipeline for sequence cleaning and phylotype assignment
(see Materials and methods). At the end of this process,
the average sequencing depth was 2,860 reads per sample.
These data were first validated by comparison with pre-
vious work, recapitulating previously observed changes in
microbial community composition during IBD and attri-
buting several to host treatment or environment. They
were subsequently associated with reference genomes in
order to discover disease-associated modulations of micro-
bial function and metabolism. A subset of 11 samples
(7 healthy, 4 CD) were subjected to whole-genome shot-
gun sequencing using the Illumina MiSeq platform at an
average depth of 119 meganucleotides per sample in order
to confirm these functional inferences.
Assessing significant covariation of microbiome structure
with host IBD status, treatment, and environment
We used a sparse multivariate statistical approach to relate
disease phenotype to microbiome structure and function
while accounting for potential correlates and confounding
factors such as treatment or smoking. Metadata features
potentially associated with each clade were first selected
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was then assessed using a multivariate linear model with
false discovery rate correction (see Materials and meth-
ods). We first investigated the resulting association of
microbial clades with IBD and with features of our
cohorts, testing all available metadata and clades from the
genus to phylum levels. Ordination of overall relationships
among samples and host status revealed several major
combinations of environmental factors that co-varied with
the microbiome (Figure 1; Additional file 1). For example,
UC covaried in this population with mesalamine treat-
ment, whereas CD patients were more often assessed by
biopsy, treated with immunosuppressants, and enriched
for Escherichia. Similarity among microbiome composi-
tions in disease subtypes reflects those previously observed
[34,35], with ileal CD (iCD) representing a strong out-
group, UC a generally less-extreme microbial phenotype
(less dissimilar from healthy subjects), and non-iCD a
broad distribution of microbiome configurations.
An important consideration that informed the remainder
of our analysis, and which is often overlooked in studies of
the microbiome, was the consistent covariation among dis-
ease status, aspects of subject environment, and micro-
biome structure. For example, the factor most associated
with changes in microbiome composition was not disease
but whether the sample origin was stool or biopsy. Biopsy
location induced minor changes in microbiome composi-
tion (Additional files 2, 3 and 4) relative to the extreme
differences between stool and biopsy communities, in
agreement with previous studies [36,37]. In this cohort,
iCD was always represented by biopsy, whereas 18.4% of
non-iCD and 36% of UC samples were biopsies. iCD was
also associated with greater likelihood of immunosuppres-
sant treatment: iCD, non-iCD, and UC patients were trea-
ted by immunosuppressants in 74.4%, 19.2% and 16% of
samples, respectively. In contrast, non-iCD and UC cases
were more likely to be treated with mesalamine or antibio-
tics: mesalamine was used for 30.2% of iCD samples, 69.2%
of non-iCD samples, and 77.3% of UC samples, while anti-
biotics were used in 2.3% of iCD, 17.9% of non-iCD, and
13.3% of UC samples. These associations lead to a range of
non-independent covariates. Although disease activity may
influence microbiome composition, after adjusting for the
other factors, it was not independently associated with a
specific shift in the microbiome composition in our analy-
sis, and there were no significant (P < 0.01) associations
between microbiome composition and gender (Additional
file 5).
The second largely independent factor influencing
microbiome composition was age, itself negatively asso-
ciated with smoking (Figure 1; Additional file 1). Twenty-
four (10.4%) of the available subjects were less than 18
years of age and 26 were 60 years or older. Aging is asso-
ciated with continual changes in the microbiome, primar-
ily a gradual decrease in Bifidobacterium as observed here
(Additional file 6) and by others [38,39]. After observing
these overall patterns of covariation among disease, treat-
ment, environment, and gut microbiome composition, we
Table 1 Characteristics of patients in this study
CD UC HS Indeterminate
n 121 75 27 8
Female gender (n) 59.5% (72) 49.3% (37) 55.6% (15) 62.5% (5)
Age (lower 95%-upper 95%) 37.3 (34.3-40.3) 41.1 (37.4-44.9) 35.1 (29.1-41.2) 26.9 (13.4-40.3)
Smoker (n)
Never 63.6% (77) 57.3% (43) 85.2% (23) 75.0% (6)
Previously 24.8% (30) 40% (30) 11.1% (3) 12.5% (1)
Current 10.7% (13) 2.7% (2) 0% (0) 12.5% (1)
Unknown 0.8% (1) 0% (0) 3.7% (1) 0% (0)
Sample
Stool (n) 51.2% (62) 64% (48) 66.7% (18) 100% (8)
Biopsy (n) 48.8% (59) 36% (27) 33.3% (9) 0% (0)
Disease
Active disease (n)
a 26.4% (32) 29.3% (22) 0% (0) 0% (0)
Ileal (n) 35.5% (43) NA NA NA
Treatment
Mesalamine (n) 55.4% (67) 77.3% (58) 0% (0) 75.0% (6)
Steroids (n) 31.4% (38) 37.3% (28) 0% (0) 50% (4)
Immunosuppressant (n)
b 38.8% (47) 16% (12) 0% (0) 0% (0)
Antibiotics (n) 12.4% (15) 13.3% (10) 0% (0) 12.5% (1)
aActive disease defined by a Harvey-Bradshaw Index (HBI) ≥ 5 or Pediatric Crohn’s Disease Activity Index (pCDAI) ≥ 10 for Crohn’s disease (CD), and Simple
Clinical Colitis Activity Index ≥ 5 or Pediatric Ulcerative Colitis Activity Index (pUCAI) ≥ 10 for ulcerative colitis (UC).
bImmunosuppressant treatments include
thiopurines, methotrexate, and anti-tumor necrosis factor-a antibody. HS, healthy subjects; NA, not applicable.
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of microbiome-disease associations in a multivariate man-
ner to account for host environment and treatment.
Microbial clades differentially abundant specifically in IBD
include Roseburia, the Ruminococcaceae, and the
Enterobacteriaceae
After adjusting for these covariates, we determined micro-
bial clades differing significantly in abundance between
h e a l t h ya n dI B Ds u b j e c t s( F i g u r e2 a ;A d d i t i o n a lf i l e1 ) .T h i s
considered age, smoking, and treatment factors (immuno-
suppressant, corticosteroids, mesalamine, antibiotics), as
well as disease activity at sampling and sample type (stool
or biopsy). Two genus-level phylotypes, Roseburia and
Phascolarctobacterium, were significantly reduced in both
UC and CD, while Clostridium increased, all with false dis-
covery rate q < 0.2. Roseburia is a clade XIVa Clostridia
and thus associated with anti-inflammatory regulatory
T cell production in the gut [40]. Cultured Roseburia have
been described as acetate utilizers and butyrate producers
[41], while cultured Phascolarctobacterium are exclusively
succinate consumers, and produce propionate when co-
cultured with Paraprevotella [42]. Thus, an IBD-associated
decrease in Roseburia and Phascolarctobacterium may
reflect a decrease in butyrate and propionate production.
The Ruminococcaceae, which are acetate producers [43],
were decreased in CD, while the Leuconostocaceae, which
produce acetate and lactate [44], were decreased in UC.
The only major clade with a significant increase in abun-
dance specific to CD was the Enterobacteriaceae, specifi-
cally Escherichia/Shigella. This family has been previously
implicated in intestinal inflammation [6,45-47].
Crohn’s disease with ileal involvement presents a distinct
microbiome phenotype including reduced
Faecalibacterium, and Odoribacter is reduced both in
iCD and in pancolonic UC
In CD patients with ileal involvement, sequences of the
Ruminococcaceae family and of Faecalibacterium in parti-
cular were dramatically reduced compared to other subjects
(Figure 2a), confirming previous studies [48,49]. Faecalibac-
terium prausnitzii, the only cultured representative of
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Figure 1 Covariation of microbial community structure in IBD with treatment, environment, biometrics, and disease subtype. Fecal and
biopsy samples from 228 IBD patients and healthy controls are plotted as squares (ileal CD) or circles (not ileal involved) and colored by disease
status. Axes show the first two components of overall variation as determined by multiple factor analysis (see Materials and methods).
Covariation in the presence of clinical factors (bold) and in microbial taxa (italic) is shown. Sample origin (biopsy versus stool) is the single most
influential factor in determining microbial community structure, accompanied by host age, treatment types, and disease (particularly ileal CD).
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Page 4 of 18Faecalibacterium, is able to metabolize both diet-derived
polysaccharides and host-derived substrates such as
N-acetyl glucosamine from intestinal mucus [50]. It is also
a major butyrate producer and exhibits anti-inflammatory
effects in a colitis setting [51]. The Ruminococcaceae repre-
sent the first step of microbiome-linked carbohydrate meta-
bolism, as they degrade several types of polysaccharides in
the lower GI tract, including starch, cellulose, and xylan
[21]. The Roseburia genus, which is significantly reduced in
all IBD patients (including iCD), and the Ruminococcaceae
are further functionally connected in that the latter con-
sume hydrogen and produce acetate that can be utilized by
Roseburia to produce butyrate [41,43]. Consistent reduc-
tions in all of these clades may thus have functional conse-
quences on the ability of the host to repair the epithelium
and to regulate inflammation.
The genera Escherichia/Shigella (indistinguishable as a
16S-based phylotype) were particularly highly enriched
in iCD (q < 0.2; Additional file 1) above their general
overabundance in CD patients. Lipopolysaccharide pro-
duced by Gram-negative bacteria such as Escherichia
coli is a canonical microbe-associated molecular pattern,
known to activate toll-like receptor 4 (TLR4) signaling
[52] and thus trigger inflammatory cascades. TLR4
expression is highly up-regulated in the intestinal
epithelium of IBD patients [53], and mutations in TLR4
are associated with both CD and UC [54]. Previous cul-
ture-based studies have found that E. coli, specifically E.
coli exhibiting pathogen-like behaviors such as adhesion
and invasiveness [55], are more frequently cultured from
iCD biopsies, and culture-independent studies have
found an enrichment in E. coli that contain virulence-
associated genes in iCD [6]. This suggests that CD-
involved ileum is a favorable milieu for establishment of
E. coli with pathobiont features, which may have impli-
cations for IBD exacerbations and its chronicity. An
inflamed ileum may furnish a specialized niche permis-
sive for microbes with enhanced fitness in inflamed
conditions.
The most severe form of UC is pancolitis, in which
UC affects the entire colon; this condition is associated
with greatly increased risk of colon cancer [56]. Patients
with pancolitis did not harbor a clear specificity in their
dysbiosis. However, both these patients and iCD patients
had a reduced abundance of the Odoribacter genus,
which belongs to the Porphyromonadaceae family and
to the Bacteroidetes phylum. As Odoribacter splanchnus
is a known producer of acetate, propionate, and butyrate
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Figure 2 Significant associations of microbial clade abundance and community ecology with IBD and treatment. (a) Taxonomic
distribution of clades significant to disease and ileal involvement. Abundant clades not significantly associated with IBD are annotated in gray
for context (top 90th percentile of at least 10% of samples and including 5+ genera). Node (non-associated clade) sizes are proportional to the
log of the clade’s average abundance. (b) Significance of association of sample ecology with disease (CD/UC, ileal/pancolonic), treatment
(antibiotics, immunosuppression, mesalamine, steroids), and environment (smoking, stool/biopsy sample origin). Diversity (Simpson’s index),
evenness (Pielou’s index), and richness (Chao1) were calculated for each community (see Materials and methods). False discovery rate q-values
are -log10 transformed for visualization, such that values > 0.60 correspond to q < 0.25. Antibiotic treatment is strongly associated with reduced
diversity, and stool samples with increased diversity relative to biopsies.
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Page 5 of 18[57], decreased Odoribacter may affect host inflamma-
tion via reduced SCFA availability.
Microbiome composition is also strongly associated with
subject age, treatment, smoking, and sample
biogeography
In the process of identifying microbiome perturbations
specific to IBD, our multivariate model simultaneously
analyzed the surprisingly diverse effects of environmen-
tal and treatment factors on GI microbial communities
(see selection in Figure 3; complete data in Additional
file 1). We observed a significant correlation between
increasing age and decreasing Bifidobacterium (Addi-
tional file 6). The Firmicutes phylum also significantly
decreased while Bacteroides increased with age in this
cohort (Additional file 1); this agrees with previous stu-
dies [38,39] and potentially reflects dietary or body
mass-related changes with increasing age, which were
not directly measured in these subjects, or host metabo-
lism modifications [58].
Critical to determining causality in links between IBD
and the gut microbiome, IBD treatments were also asso-
ciated with alterations in microbiome composition.
Mesalamine (5-aminosalicylic acid) is a bowel-specific
aminosalicylate drug. Although its exact mode of action
is unknown, it is thought to act as an antioxidant and to
decrease intestinal inflammation, in part by peroxisome
proliferator-activated receptor-g (PPARg) activation and
inhibition of NFB and pro-inflammatory eicosanoid
production. Here, its use was linked to strong reduc-
tions in Escherichia/Shigella (> 100% of average abun-
dance, q < 0.04; Additional file 7), in agreement with a
recent study [59]. Both 5-aminosalicylic acid and immu-
nosuppressant treatment were associated with modest
increases in Enterococcus, the only genus perturbed in
immunosuppressant-treated patients with low false
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Figure 3 Select microbial clades significantly linked to host environment and treatment. Anaerostipes decreased significantly in the gut
communities of smokers, and Dorea, Butyricicoccus, and Coriobacteriaceae were among the taxa most reduced in patients receiving antibiotics
(Abx). These associations were significant even in a multivariate model accounting for sample biogeography and disease status. Sqrt, square root.
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Page 6 of 18discovery rate (also > 100% of average abundance, q <
0.09).
Antibiotics were among the strongest factors associated
with a reduction in ecological diversity (Figure 2b). Many
individual clades were greatly reduced or nearly absent
after administration of antibiotics, including the Collin-
sella, Dorea, Butyricicoccus, Subdoligranulum,a n dAceti-
vibrio (all q < 0.2; Additional file 1). These genera are
predominantly from the Clostridiales order, Gram-posi-
tive and anaerobic bacteria that are targeted by the anti-
biotics commonly used in IBD, such as ciprofloxacin and
metronidazole.
Smoking is likely the best-known environmental factor
that impacts IBD [60]. It is associated with increased risk
of CD and is conversely protective towards developing
UC [61]. The only common organism to which tobacco
usage was linked in these individuals was Anaerostipes
(Firmicutes phylum), which decreased (> 60% average
abundance, q < 0.15; Figure 3) in current or former
tobacco users, beyond any change due solely to smokers’
higher average age. The Anaerostipes genera can utilize
lactate to produce butyrate [62], which is beneficial to
colonic health.
Finally, as previously mentioned, samples of the stool as
opposed to mucosal biopsies differed strongly in micro-
biome composition (Additional file 2). More than 70
clades were significantly over- or under-enriched in stool
samples relative to biopsies at q < 0.2. This effect extended
to entire phyla, as the Firmicutes were approximately two-
fold more abundant in stool (Additional file 1). Microbial
habitat dictates the composition of microbial communities
[36]; in the GI tract, this has been suggested to occur on
biogeographical scales of intestinal regions [37,63] or even
millimeters apart [64,65], and luminal/mucosal differences
may be further perturbed by bowel preparation prior to
colonoscopy [66]. The data did not suggest that the lumi-
nal and mucosal communities were independent; rather,
all 14 clades significantly associated with IBD retained the
same trend when stratified by sample origin (Additional
file 8). The fecal microbiome appeared to convey a consis-
tent but numerically transformed function of mucosal
communities, both of which shifted in composition in
association with host environment, treatment, and disease.
In a closer analysis of intestinal biogeography as
reflected by biopsies drawn from distinct regions, differ-
ences in most clades were modest and correlated largely
with previously described changes in pH (Additional files
2, 3 and 9) [67]. The clades with the largest regional
changes included the Roseburia and Ruminococcaceae,
with lower abundance in the low-pH terminal ileum,
transverse, and right colon; Alistipes, following a similar
pattern; and the Fusobacteria and Enterobacteriaceae, with
an opposite pattern of somewhat increased abundance in
the ileum and right colon. Particularly as the former have
also been associated with the colorectal cancer microenvir-
onment in previous work [68,69], it is of note that these
variations in the microbiota with respect to biogeography
and pH are similar to those we observed with respect to
IBD and potentially redox status as detailed below.
The metagenomic abundances of microbial metabolic
pathways are more consistently perturbed in IBD than
are organismal abundances
We continued our analysis by combining community com-
position with over 1,200 annotated genomes from the
Kyoto Encyclopedia of Genes and Genomes (KEGG) cata-
log [70]. The genes annotated within each available refer-
ence genome were used to provide an approximate gene
catalog for each community (see Materials and methods),
which we reconstructed into metabolic pathways (Figure 4)
and smaller modules and biological processes (Figure 5;
Additional file 10) as previously described [71]. Pathway,
module, and process abundances were then associated with
disease and host environment using the same sparse multi-
variate model with which microbial abundances were
assessed (Additional files 11, 12 and 13).
Considering only the contrast between IBD (CD or
UC) and healthy subjects, 24 of 200 (12%) total meta-
bolic modules were differentially abundant at q < 0.2.
This is in stark contrast to the microbial shifts dis-
cussed above, in which only 6 of 263 (2%) genus-level
clades reached this significance threshold. Even in the
absence of metagenomic or metatranscriptomic data
and only leveraging the genes and pathways in refer-
ence genomes associated with these communities,
changes in microbial function were more consistent
than changes in community structure. This has been
noted in environmental communities [72] and sug-
gested with respect to obesity and other biometrics
[ 7 3 , 7 4 ] ,b u tt od a t ei th a sn o tb e e nr e p o r t e df o rd i s -
ease-linked dysbioses or IBD.
We validated these functional shifts by shotgun meta-
genomic sequencing of the small subset of available sam-
ples with appropriate stool DNA, seven healthy controls
and four CD patients (Additional file 14). These were
sequenced to a shallow depth averaging 119 meganucleo-
tides per sample of 150-nucleotide paired-end Illumina
MiSeq reads, reducing our effective limit of detection but
otherwise providing close agreement with inferred meta-
bolic shifts in the IBD metagenome. Of the modules
highlighted below and in Figure 5, one (cobalamin bio-
synthesis) fell below the limit of detection, and the
remaining six retained the expected trend of over- or
under-enrichment in Crohn’s disease, as did additional
processes detailed below, including glycolysis and bacter-
ial secretion.
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are reduced in the IBD microbiome in favor of nutrient
uptake
We observed that even basic GI microbiome metabo-
lism was altered in both UC and CD. Amino acid
metabolism showed major perturbation: genes for the
metabolism and biosynthesis of nearly all amino acids
(particularly histidine and lysine) decreased in abun-
dance (Figure 4), while arginine, histidine, and lysine
transport (Figure 5) gene abundance increased. In iCD
we also observed a decrease in glutamine-related func-
tional modules, which would lead to a lower amount of
glutamate required for gamma-aminobutyric acid,
ornithine, and arginine biosynthesis; abundance of all
three of these modules also decreased. In marked
contrast to the other amino acids, genes for metabo-
lism of the sulfur-containing amino acid cysteine sig-
nificantly increased in abundance, with even greater
increase in iCD. This corresponded with an overrepre-
sentation of genes related to sulfate transport in UC
and CD (Figure 5), and in increase in sulfur and nitro-
g e nm e t a b o l i s mi nC D( F i g u r e4 ) .
CD was associated with increased abundance of many
genes related to carbohydrate transport (Figure 5). There
were large increases in pentose phosphate pathway and
fructose/mannose metabolism gene abundance in iCD
(Figure 4), which were accompanied by increase in carbo-
hydrate metabolism, but they were not significant in UC
and CD. In addition, iCD showed increased abundance of
transporter genes for glucose, hexoses, maltose, and
Microbial functions (KEGG pathways) differentially abundant in IBD
Nitrogen metabolism
Fructose and mannose metabolism
Riboflavin metabolism
Sulfur metabolism
Bacterial secretion system
Cysteine and methionine metabolism
Butanoate metabolism
Lysine biosynthesis
Pentose phosphate pathway
Relative abundance
0.08
UC
0.14 0.12 0.10
Healthy
CD without Ileal
CD with Ileal
Figure 4 Microbial metabolic pathways with significantly altered abundances in the gut communities of IBD patients. Abundance of
KEGG metabolic pathways in microbiome samples is colored by disease state and, when significant, stratified by ileal involvement. Basic
metabolism (for example, most amino acid biosynthesis) and SCFA production were reduced in abundance in disease, while biosynthesis and
transport of compounds advantageous for oxidative stress (for example, sulfur, cysteine, riboflavin) and adherence/pathogenesis (for example,
secretion) were increased.
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a decrease in both butanoate and propanoate metabolism
in iCD (Figure 4), suggestingap o t e n t i a ld e c r e a s ei n
SCFA production by the microbiome, possibly due to the
observed decrease in Roseburia and Faecalibacterium.
We saw an increase in glutathione transport gene abun-
dance in UC and CD (Figure 5) and an increase in glu-
tathione metabolism gene abundance in UC. Glutathione
is a tripeptide of cysteine and glutamate, synthesized by
Proteobacteria and a few streptococci and enterococci
[75], which allows bacteria to maintain homeostasis during
oxidative or acid stress. Inflammatory cascades include
production of highly reactive oxygen and nitrogen meta-
bolites, which are greatly increased in active IBD [76].
Lamina propia monocytes also release homocysteine dur-
ing inflammation, which further contributes to oxidative
stress; IBD is associated with higher levels of both mucosal
and serum homocysteine [77]. Thus, the increases in
sulfate transport, cysteine metabolism, and glutathione
metabolism may reflect a mechanism by which the gut
Microbial metabolism (KEGG modules and GO Terms) differentially abundant in IBD
PTS system, N−acetylgalactosamine−
specific II component
Glutathione transport system
Cobalamin biosynthesis, cobinamide => cobalamin
Lysine/arginine/ornithine transport system
Maltose/maltodextrin transport system
Sulfate transport system
Ornithine biosynthesis, glutamate => ornithine
Oligosaccharide transport
Polysaccharide catabolic process
Cysteine metabolic process
Glutamine family aminoacid metabolic process
Cellular lipid metabolic process
Nucleotide metabolic process
Relative abundance
0.00 0.01 0.02 0.03 0.04 0.05
0.00 0.02 0.04 0.06 0.08 0.10 0.12 0.14
UC
Healthy
CD without Ileal
CD with Ileal
(a)
(b)
Figure 5 Small metabolic modules and biological processes with significantly altered abundances in the IBD microbiome. (a, b) Small
(typically 5 to 20 gene) KEGG modules (a) and independently defined biological processes from the Gene Ontology (b) were assessed for
significant association with disease and ileal involvement as in Figure 4. Metabolism related to oxidative stress (for example, glutathione and
sulfate transport) and for pathobiont-like auxotrophy (for example, N-acetylgalactosamine and amino acid uptake) is increased, while several
basic biosynthetic processes are less abundant.
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inflammation.
Extreme functional shifts in iCD include changes in redox
metabolism, enrichment of signaling/secretion, and
suggest a ‘pathobiont-like’ invasive metagenome
CD with ileal involvement exhibited specific dysfunction
at the module level. It was associated with an increase in
several modules involved in glycolysis and carbohydrate
transport and metabolism (Figure 5). Conversely, iCD
exhibited lower abundance of genes involved in lipid
metabolism and catabolism, confirming a major imbal-
ance in energy metabolism. We observed a global
decrease in nicotinamide, purine, and pyrimidine nucleo-
tide biosynthesis modules in iCD, CD, and UC (Figure 5).
There was a decrease in vitamin biosynthesis associated
with iCD, but increases in thiamine and particularly ribo-
flavin metabolism modules (Figure 4). Interestingly, this
pathway is fed by the pentose phosphate pathway, which
was also overrepresented in iCD. Riboflavin is necessary
for regenerating oxidized glutathione back to its reduced
form, and is thus essential for pH and oxidative stress
homeostasis, as is NADPH, a product of the pentose
phosphate pathway. Metabolism of the sulfur-containing
amino acids cysteine and methionine was increased in
iCD, in marked contrast to the IBD-associated decreases
in the non-sulfur-containing amino acids such as lysine
and glutamine. As homocysteine is easily convertible to
methionine, this may indicate a further mechanism of
maintaining redox homeostasis. Alternatively, this may
be connected to the iCD-specific increase in carbohy-
drate metabolism, as cysteine may be metabolized to
pyruvate.
Finally, genes involved in pathogenesis processes, such
as secretion systems and adherence/invasion, were over-
represented in iCD (Figure 4). For example, genes
involved in the shigellosis pathway were more abundant
in CD, and type II secretion genes were more abundant
in iCD. Type II secretion is involved in the secretion of
cell wall-degrading enzymes [78] and the secretion of
toxins such as heat-labile enterotoxin, similar to cholera
toxin [79]. These functions are typical of pathobiont
adherent-invasive E. coli, which have been observed to
increase in iCD in our own study and others [6,55]. This
may be associated with tissue damage, either primarily as
a result of toxin secretion, or secondarily as a result of
stimulated cytokine production. This tissue destruction is
a likely source of metabolites for microbial overgrowth,
selecting for auxotrophic specialists able to thrive in this
environment and resulting in the microbiome-wide loss
of basic biosynthetic processes (Figures 4 and 5). This
would in turn lead to further tissue breakdown, bacterial
overgrowth, and community structural and functional
dysbiosis.
Discussion
The GI microbiome influences dietary energy extraction,
immune system development, vitamin production, and
drug metabolism, yet most molecular and metabolic
functions of the bacteria of the GI microbiome are
uncharacterized [20]. To gain insight into the functional
consequences of IBD-associated dysbiosis, we used a
novel approach pairing microbial community 16S gene
sequence profiles with information from the closest avail-
able whole-genome sequences. This defined an inferred
metagenome and thus complement of metabolic func-
tional modules for each microbiome in this study. This
allowed us to identify unique functional perturbations in
the microbiomes of IBD patients. Interestingly, although
we identified only nine changes in bacterial clades that
associated with UC (of 350 total, 2.6%), we identified 21
statistically significant differences in functional pathways
and metabolic modules (of 295, 7.1%); this pattern held
for CD and iCD function as well. This underscores the
fact that phylogenetically diverse changes in the composi-
tion of the GI microbiome can be functionally coordi-
nated and lead to major modifications in the metabolic
potential of the microbiota.
The microbial metabolic information available in this
study represents only one step in the functional investiga-
tion of the IBD microbiota, as it is an accurate but approx-
imate inference using prior knowledge of microbial
genomes. The metagenomes inferred from our 16S data
were supported by shotgun sequencing of a subset of sam-
ples, providing one confirmation that they were represen-
tative of community functional capability. As sequencing
costs continue to fall, rich metagenomic data for dozens
or hundreds of samples will further improve our ability to
resolve species-level gene function in communities. Of
course, a community expresses only a variable subset of its
functional capability at any given time, in response to
environmental stimuli. Thus, metatranscriptomic, proteo-
mic, and metabolomic data will continue to add to our
understanding of which of a community’s potential func-
tions are most strongly affecting the host during inflam-
matory disease.
Combining shifts in functional module abundance with
prior knowledge of these metabolic pathways provides
fresh insight into microbiome dysfunction in IBD. Meta-
bolism of the sulfur-containing amino acid cysteine was
increased in both UC and CD. This was accompanied by
increases in riboflavin metabolism, glutathione transpor-
ters, and the N-acetylgalactosamine phosphotransferase
system. Mucin, which is rich in cysteine and glycosylated
sugars, is abundant in the intestinal epithelium, and it is
upregulated during inflammation. The increases in
cysteine metabolism and N-acetylgalactosamine trans-
porters may reflect a shift in the microbiome towards
greater abundance of microbes that use mucin as a
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gests activity at the mucosa and this may be problematic
for a damaged IBD epithelium with compromised barrier
function.
Alternatively, the increased biosynthesis of cysteine (a
precursor of glutathione) and of glutathione transport
modules may speak to the microbiome’sr e s p o n s et ot h e
oxidative stress (high levels of reactive oxygen and nitro-
gen species) of the inflamed IBD gut [76]. In support of
this concept, we found that riboflavin metabolism, which
is required to convert glutathione between its oxidized
and reduced forms, is increased in iCD. Furthermore, the
pentose phosphate pathway, which produces the NADPH
also required for glutathione reduction, is increased as
well. Recent studies have shown that redox stress allows
Salmonella to use ethanolamine as a carbon source [80]
and allows enterohemorrhagic E. coli to use it as a nitro-
gen source [81], thus conferring a competitive advantage
to these microbes. This raises the interesting possibility
that E. coli or related species in IBD may be highly repre-
sented because they gain a competitive advantage from
oxidative stress and are better able to compensate for it
with glutathione production.
In both UC and CD, there were decreases in the bio-
synthesis of lysine, arginine, and histidine in favor of trans-
port in both UC and CD; a further decrease in tryptophan
metabolism was associated with iCD. The data showed
additional broad decreases in many essential processes,
such as cobalamin synthesis, purine and pyrimidine bio-
sythesis, lipid catabolism, and phospholipid metabolism, as
well as marked increases in transport. This overall
decrease in abundance of genes for amino acid and
nucleotide biosynthesis bears striking resemblance to the
lifestyle of highly symbiotic bacteria that are intrinsically
auxotropic and also of some pathobionts (Figure 6). One
such example are segmented filamentous bacteria (SFB), a
symbiont that belongs to the Candidadatus Arthromitis, a
sub-group of clade I (sensu stricto) Clostridia. A recently
sequenced SFB genome lacked genes for nucleotide bio-
s y n t h e s i sa sw e l la sn e a r l ya l lv i t a m i n sa n da m i n oa c i d s
[82,83]. SFB are often abundant in the rodent terminal
ileum and are responsible for the maturation of Th17 cells
[84], which play an important role in CD-associated
inflammation [85]. To date, neither SFB nor phylogeneti-
cally related sequences have been observed in humans
[82,86]; this was also true in our data (zero 16S sequences
with > 90% identity to X77814 SFB). However, a functional
trend similar to SFB was observed in these IBD commu-
nity metagenomes, as biosynthetic mechanisms through-
out central carbon metabolism, amino acid biosynthesis,
and nucleotide maintenance were all reduced (Figures 4
and 5), hinting that humans may host functional equiva-
lents of SFB-like pathobionts that increase in IBD but are
not phylogenetically close to Candidatus Arthromitis.
Host tissue destruction, either inflammation-mediated or
bacterially mediated, woul dp r o v i d ear e a d yn u t r i e n t
source (Figure 6).
Conclusions
The data presented here show that IBD and iCD in parti-
cular are associated with a dysbiosis characterized by
changes in Firmicutes and Proteobacteria phyla. Environ-
mental factors and, notably, treatments were also asso-
ciated with independent changes in the GI microbiome;
these must be taken into account during future studies of
the microbiota in IBD. These perturbations in bacterial
composition, although modest, were associated with major
perturbations of GI microbiome function, which revolved
around metabolism in the presence of oxidative stress and
perturbed nutrient availability during tissue damage.
Further studies, particularly including transcriptomic, pro-
teomic, or metabolomic characterization, longitudinal
data, and dietary metadata, will be needed to additionally
define the consequences of the IBD-associated micro-
biome dysfunction on the host and the specific mechan-
isms by which they are carried out or regulated by the
microbiota.
Materials and methods
The OSCCAR and PRISM cohorts
The Ocean State Crohn’s and Colitis Area Registry
(OSCCAR) is a state-based, prospective inception cohort
of IBD patients that was designed to study the epidemiol-
ogy of IBD, to determine the incidence of IBD in Rhode
Island, and to extrapolate these rates to the general popu-
lation of the United States. The diverse population of
over 1 million, limited geographic range, and well-cir-
cumscribed gastroenterology community of Rhode Island
were ideal circumstances for establishing a prospective
inception cohort of IBD patients. All but one of the 98
gastroenterologists/colorectal surgeons in Rhode Island
agreed to refer patients to OSCCAR, and 11 gastroenter-
ologists practicing in Massachusetts just over the Rhode
Island border also agreed to refer their newly diagnosed
IBD patients who resided in Rhode Island. Enrollment
began 1 January 2008. All Rhode Island residents with a
newly confirmed diagnosis of CD, UC, or indeterminate
colitis were eligible for inclusion (within 12 months from
diagnosis). Ethnic background of the subjects was not
available for consideration in the analysis, and indetermi-
nate colitis patients were analyzed only for other meta-
data and not for IBD diagnosis. Diagnosis of CD, UC, or
indeterminate colitis was made by endoscopic, patholo-
gic, or radiographic findings according to the criteria of
the National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) IBD Genetics Consortium.
OSCCAR research protocols were reviewed and approved
by three institutional review boards (Lifespan (#0214-07),
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001705), and the Program for the Protection of Human
Subjects/Mount Sinai School of Medicine (#11-01479)),
and all experiments adhered to the regulations of these
review boards. Informed consent and HIPAA (Health
Insurance Portability and Accountability Act) authoriza-
tion were obtained from each subject prior to study parti-
cipation. Individuals diagnosed with IBD prior to the
study start date, pregnant women, those unwilling to pro-
vide informed consent for study participation, and those
who were prisoners at the time of diagnosis were not per-
mitted to enroll.
T h eP r o s p e c t i v eR e g i s t r yi nI B DS t u d ya tM G H
(PRISM) is a referral center-based, prospective cohort of
IBD patients. Enrollment began 1 January 2005. Patients
aged 18 years and older with a diagnosis of CD or UC
based upon standard endoscopic, radiographic, and histo-
l o g i cc r i t e r i aw e r ee l i g i b l et o participate. Controls con-
sisted of healthy patients aged 18 years and older, from
whom biopsies were obtained during colonoscopies per-
formed for screening purposes.
Patients were excluded from the healthy volunteer group
for current acute illness, if awaiting transplant, or if
chronically ill (for example, renal failure, diabetes, conges-
tive heart failure). During routine colonoscopies, subjects
w e r eo f f e r e dt h eo p p o r t u n i t yt od o n a t eb i o p s ys a m p l e s .
After sampling, intestinal biopsies were stored in 5% gly-
cerol at -80°C until DNA extraction. Stool samples were
kept at 4°C for less than 24 h before storage at -80°C until
DNA extraction. PRISM research protocols were reviewed
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Clade IV and
XIVa Clostridia 
LPS production, virulence factor production
Tissue
destruction 
Short chain fatty acid production
Purine and pyrimidine biosynthesis 
Lysine and histidine biosynthesis
NAG transport
Mucin biosynthesis/degradation
Redox homeostasis
Glutathione biosynthesis
Sulfur amino acid metabolism
Inflammation
Methionine
Cysteine
Cysteine + Glutamine
Fiber
Acetate
Butyrate
Propionate
CO2
H2
Homocysteine
Glutathione
Cysteine
Sulfate galactosamine
N-acetyl
+ Mucin
Glutathione =
GSH
GSSG
Riboflavin NADPH
NADP+
E. coli
Auxotrophic specialists
Figure 6 Proposed metabolic roles of the gut microbiome in IBD. Host-mediated processes (blue text) create an environment of oxidative
stress in the intestine, which is more favorable to Enterobacteriaceae (increased abundance) than to clades IV and XIVa Clostridia (decreased
abundance). This study’s inferred IBD metagenomes include broadly increased oxidative metabolism, decreased SCFA production, and increased
mucin degradation relative to healthy subjects. These processes all occur within microbes and rely on transport of small molecules to and from
the lumen. The resulting tissue-destructive environment provides nutrients such as nucleotides and amino acids, which allow for increased
growth of auxotrophic ‘specialists’. Bacterial clades of interest are indicated in orange, bacterially mediated processes increased in IBD in red, and
processes that decrease in green. Metabolic pathways differential in our IBD communities are contained in blue boxes. GSH and GSSG indicate
reduced and oxidized forms of glutathione. LPS, lipopolysaccharide; NAG, N-acetyl galactosamine.
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tee (#2004-P-001067), and all experiments adhered to the
regulations of this review board.
DNA extractions
DNA from stool and biopsy samples was extracted using
the QIAamp DNA Stool Mini Kit (Qiagen, Inc., Valencia,
CA, USA) according to manufacturer’s instructions and as
described previously [87]. The manufacturer’sp r o t o c o l
was altered to accommodate larger stool volumes and to
improve homogenization using bead-beating at several
steps: a) a minimum of 2 ml of Buffer ASL and 300 mg of
stool was used in the protocol; b) a ratio of 700 μl of Buf-
fer ASL per 100 mg of stool weight was used for larger
volumes using no more than 1,500 mg of stool and 10.5
ml of Buffer ASL; c) following the addition of Buffer ASL
to each sample (step 2), 0.70 mm Garnet Beads (MO BIO
Laboratories, Inc., Carlsbad, CA, USA) were added to the
suspension and vortexed for 10 seconds; d) a second bead-
beating was performed following the heating of the sus-
pension (step 3) in 0.1 mm Glass Bead Tubes (MO BIO
Laboratories, Inc.), and vortexed for 10 minutes.
Amplification and 454 sequencing of the 16S gene
The 16S gene dataset consists of 454 FLX Titanium
sequences spanning the V3 to V5 variable regions.
Detailed protocols used for 16S amplification and
sequencing are available on the Human Microbiome
Project Data Analysis and Coordination Center website
[88]. In brief, genomic DNA was subjected to 16S
amplifications using primers designed incorporating the
FLX Titanium adapters and a sample barcode sequence,
allowing directional sequencing covering variable regions
V5 to partial V3 (primers: 357F 5’-CCTACGGGAGG-
CAGCAG-3’ and 926R 5’ CCGTCAATTCMTTTRAGT-
3’). PCR mixtures (25 μl) contained 10 ng of template,
1× Easy A reaction buffer (Stratagene, La Jolla, CA,
USA), 200 mM of each dNTP (Stratagene), 200 nM of
each primer, and 1.25 U AccuPrime hifi cloning enzyme
(Invitrogen, Carlsbad, CA, USA). The cycling conditions
for the V3-V5 consisted of an initial denaturation of 95°
C for 2 minutes, followed by 25 cycles of denaturation
at 95°C for 40 s, annealing at 50°C for 30 s, extension at
72°C for 5 minutes and a final extension at 72°C for 7
minutes. Amplicons were confirmed on 1.2% Flash Gels
(Lonza, Rockland, ME, USA), purified with AMPure XP
DNA purification beads (Beckman Coulter, Danvers,
MA, USA) according to the manufacturer, and eluted in
25 μl of 1× low TE buffer (pH 8.0). Amplicons were
quantified on Agilent Bioanalyzer 2100 DNA 1000 chips
(Agilent Technologies, Santa Clara, CA, USA) and
pooled in equimolar concentration. Emulsion PCR and
sequencing were performed according to the manufac-
turer’s specifications.
Processing sequencing samples
Sequences were processed in a data curation pipeline
implemented in MOTHUR [89], which removed
sequences from the analysis if they were less than 200
nucleotides or greater than 600 nucleotides, had a low
read quality score (< 25), contained ambiguous charac-
ters, had a non-exact barcode match, or had more than
4 mismatches to the reverse primer sequences (926R).
Remaining sequences were assigned to samples based
on barcode matches, and barcode and primer sequences
were then trimmed. Chimeric sequences were identified
using the ChimeraSlayer [90] algorithm, and reads were
classified with the MSU RDP classifier v2.2 [91] using
the taxonomy maintained at the Ribosomal Database
Project (RDP 10 database, version 6). Sequencing depth
after processing averaged 2,860 (standard deviation
1,730) reads per sample.
Metagenome inference from microbiome composition
To construct an approximate gene catalog for each sam-
ple community, we used the gene content of 1,119 KEGG
reference genomes to infer the approximate gene content
of our detected phylotypes. We first matched the Fas-
tTree GreenGenes (GG) phylogeny [92] annotated with
these KEGG genomes’ organisms against the RDP taxon-
omy used for phylotyping. Each clade in the RDP taxon-
omy was mapped to the clade within the GG phylogeny
that maximized the Jaccard index of overlapping named
descendant genomes. That is, each genus-level phylotype
was assigned to the GG clade containing the most gen-
omes from that genus and fewest from other genera.
Higher-level clades continued this pattern using the Jac-
card index as an optimality criterion. The gene contents
for ancestral clades were then reconstructed across the
GG tree, beginning with each reference genome (tree
l e a f )s u m m a r i z e da sav e c t or of KEGG ortholog (KO)
[70] copy numbers (0, 1, or multiple copies of the gene
annotated within the genome). Gene contents of each
parent GG clade g were calculated by averaging all des-
cendant genomes’ h KO vectors, with weight w(g, h)
inversely exponential to phylogenetic distance:
  g =

h∈descendants(g)
w(g,h)
 
h/

h∈descendants(g)
w(g,h)
w(g,h)=2 =dist(g,h)
for GG tree nodes g and h separated by phylogenetic
branch length dist(g, h) and annotated with KO genome
vectors
  g and
 
h.
Using this vector representation of genomes, the
abundance of an individual gene family (KO) i in a com-
munity due to the presence of a specific phylotype g is
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  g[i] and
the measured abundance of phylotype g.T h e r e f o r e ,t h e
total relative abundance of each KO was estimated for
each sample by adding the individual contributions of
all phylotypes present in the sample. Using this method,
we inferred the functional composition for each sampled
community. The inference process’s accuracy was vali-
d a t e db yc o m p a r i n gi n f e r r e dK Oa b u n d a n c e si n1 6 S
datasets from the Human Microbiome Project with their
metagenomically sequenced counterparts (Additional
file 15).
Metabolic pathway reconstruction
Inferred per-community gene (KO) abundances were
subsequently reconstructed into microbial pathway rela-
tive abundances using HUMAnN, the Human Micro-
biome Project metabolic reconstruction pipeline [71].
KOs were grouped into pathways represented as gene
sets using HUMAnN, which chooses pathways by maxi-
mum parsimony using MinPath [93] and computes each
pathway’s relative abundance as a smoothed average
over all genes within it, taking into account outliers and
gap filling. We ran HUMAnN three times to reconstruct
three complementary types of pathways from these
genes: small metabolic modules (using KEGG’s conjunc-
tive normal form logic), large metabolic pathways, and
Gene Ontology terms (using annotation-to-KO map-
pings from nine well-characterized KEGG microbes:
ban, cje, cpe, eco, nse, pae, sce, son, and vch). For each
of these three types of pathway, HUMAnN input the
inferred relative abundances of all genes in each sample,
and output the relative abundances of pathways within
the sample. Subsequent analysis handled these sample-
by-pathway relative abundances in the same manner as
sample-by-clade microbial abundances.
Significant associations of microbial clades and pathways
with sample metadata
Inverse Simpson diversity, Chao1 richness (using the R
fossil package), and Pielou evenness were calculated for
clade abundance, KEGG pathway and module abun-
dance, and Gene Ontology term abundance [94-97].
N e x t ,d a t aw e r ep r e - p r o c e s s e df o rq u a l i t yc o n t r o lb e f o r e
modeling. Clinical metadata were removed when more
than 10% of data were missing, or when they did not vary
in value over the available samples. Clades, pathways, and
features of very low abundance (< 0.001 in ≥ 90% of sam-
ples) and feature outliers outside of the lower or upper
outer fence (3× interquartile range) were removed. Miss-
i n gd a t aw e r ei m p u t e df o rs i g nificance testing with the
mean abundance of the sample; missing factor metadata
were imputed with a ‘NA’ factor level using the na.gam.
replace function from the R package [98]. Unless stated
otherwise, all subsequent analyses and calculations were
performed using these processed data. After processing,
228 and 231 samples passed quality control for
clade abundance and functional abundance analyses,
respectively.
Finally, clades and functions were tested for statisti-
cally significant associations with clinical metadata of
interest by using a novel multivariate algorithm. Each
clade (excluding ecological measures) was normalized
with a variance-stabilizing arcsine square-root transfor-
mation and evaluated with a general linear model (in R
using the glm package). Model selection for sparse data
was performed per clade using boosting (gbm package
[99]). A multivariate linear model associating all avail-
able metadata with each clade independently was
boosted, and any metadata selected in at least 1% of
these iterations was finally tested for significance in a
standard generalized linear model. This composite
model was thus of the form:
arcsin(
√
yi)) = β0 +

p
βpXi,p + εi,i = 1,...,n
where p are the clinical metadata selected from
boosting.
Within each metadatum/clade association indepen-
dently, multiple comparisons over factor levels were
adjusted using a Bonferonni correction; multiple hypoth-
esis tests over all clades and metadata were adjusted to
produce a final Benjamini and Hochberg false discovery
rate [100]. Unless otherwise indicated, significant associa-
tion was considered below a q-value threshold of 0.25;
the KEGG pathway sulfur metabolism (ko00920) had an
average q-value of 0.26 for association with Crohn’sd i s -
ease. Multiple factor analysis was performed to visualize
the relationships within heterogeneous factor data as well
as with a select group of taxa found to be significantly
associated with metadata (using the FactoMineR R pack-
age [101]). Total abundances and significant associations
between metadata, taxa, and functions are listed in Addi-
tional files 1 and 11.
Sequence alignment for segmented filamentous bacteria
To determine whether SFB were present in samples, three
sequences of SFB (X80834, X87244, and X77814) from
three species (chicken, rat, and mouse) were aligned by
b l a s t n ,u s i n gb o t ha2 0a n d1 5s e e dw o r d .N os e q u e n c e s
were found with ≥ 95% identity over an alignment length
of at least 100 nucleotides. The average sequence length
from the study was 435 nucleotides.
Shotgun metagenomic sequencing
To provide internal validation of inferred microbial
community gene and pathway compositions, stool DNA
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subjected to metagenomic shotgun sequencing. Libraries
were constructed with the Illumina Nextera XT kit and
sequenced on an Illumina MiSeq using 2 × 150 bp
paired-end sequencing according to the manufacturer’s
instructions. This resulted in sequencing depths ranging
from 3.9 to 270 meganucleotides, average 119 meganu-
cleotides, from which microbial community function
was determined with HUMAnN [71] as described above.
Sequence accession numbers and availability
Sequences generated in this study are publicly available
(NCBI BioProject ID numbers 82111 and 175224).
Additional material
Additional file 1: Taxa significantly associated with IBD status or
subject metadata using a boosted general linear model.A
multivariate analysis was performed to associate each microbial clade
with a sparse selection of disease status and clinical metadata (selected
through boosting; see Materials and methods). All clades and metadata
in these associations are given with nominal P-values from the
multivariate linear model and with Benjamini and Hochberg (BH)
corrected false discovery rate (q-values) up to a threshold of 0.25. In this
and all other supplemental tables, blank spaces indicate values that were
not significant but are shown for comparison with related significant
data.
Additional file 2: Effects of biogeography on gut microbiome
composition differentiates stool and biopsy communities. The
composition of phyla stratified by biopsy location or fecal sample origin
mainly differentiates stool and biopsy communities. Sample count per
location is indicated in parentheses. Biopsy locations (above) do not
substantially differ in composition, while biopsies compared to stool
(below) differ significantly in all phyla.
Additional file 3: Univariate analysis of associations between
microbial composition and biopsy location. A univariate analysis for
associations between taxa and biopsy sites was conducted using LEfSe
[102] considering the six regions annotated for these samples: 1)
terminal ileum (TI), 2) cecum, 3) left colon, 4) transverse colon, 5) right
colon, and 6) sigmoid colon and rectum. (a) Relatively few clades were
strongly associated with biopsy locations, and these tended to mirror
expected intestinal pH and the clades described here as particularly
affected by disease-linked inflammation. (b-g) Abundant major clades,
including the Firmicutes (b), showed extremely modest variations with
intestinal region, driven by specific members depleted in low-pH regions,
including Roseburia (c) (high in the left and sigmoid colon),
Ruminococcaceae (d), and to a lesser degree Alistipes (e). Clades enriched
in low pH regions included Fusobacterium (f) (high in TI and right colon)
and Enterobacteriales (g) (particularly in TI).
Additional file 4: Locations of patient biopsies. Distribution of biopsy
samples available for this study as classified by the OSCCAR and PRISM
cohort collection protocol.
Additional file 5: Univariate analysis of associations between
microbial composition and gender. A univariate test for associations of
subject gender with microbial clades was conducted using LEfSe [102],
resulting in few and weak associations concordant with previous studies
[5]. Here, Clostridium and the Streptococcaceae were weakly associated
with gender at P < 0.05, but did not remain significant at P < 0.1.
Additional file 6: Bifidobacterium genus abundance decreases
significantly with age. The association of Bifidobacterium abundance
with disease status and clinical metadata (including age) was determined
to be significant in these data using a sparse general linear model. Clade
abundances were transformed with the arcsine square-root
transformation for proportional data (y-axis). Size of effect, standard
deviation, P-value (p) and Benjamini and Hochberg false discovery rate
(q) are shown in parentheses, and the line of best fit in green.
Additional file 7: Escherichia/Shigella abundance is significantly
decreased in mesalamine-treated subjects. The association of these
genera (indistinguishable by 16S rRNA gene sequencing) with disease
status and clinical metadata (including mesalamine treatment) was
determined to be significant using a sparse general linear model (see
Materials and methods). Clade abundances were transformed with the
arcsine square root transformation for proportional data and are plotted
along the y-axis as two notched box plots (samples without and with
mesalamine use). Size of effect, standard deviation, P-value (p) and q-
value (q) are shown in parentheses.
Additional file 8: Stratification of clades associated with IBD status
by sample biogeography. Fifteen microbial clades were significantly
associated specifically with IBD status (q < 0.25) using a multivariate
linear model incorporating clinical metadata (see Materials and methods).
Although this model putatively asserts that this association holds
regardless of sample origin (biopsy or stool), we verified this by
stratifying each clade’s abundance by sample type, stool (1) or biopsy (0).
Green coloring indicates that a clade’s abundance was significantly
reduced in IBD using the full model, red increased. These trends are
uniformly preserved after explicit stratification by stool versus biopsy
sample origins.
Additional file 9: Univariate associations of microbial composition
with biopsy location. Results of a LEfSe analysis of the six location
categories available for biopsies in this study, excluding two
anatostamosis samples.
Additional file 10: Covariation of microbial community function in
IBD with treatment, environment, biometrics, and disease subtype.
Fecal and biopsy samples from 231 IBD patients and healthy controls are
plotted as squares (iCD) or circles and colored by disease status. Axes
show the first two components of overall variation as determined by
multiple factor analysis (see Materials and methods). Clinical and
environmental covariates are shown in bold, while individual microbial
functions (Gene Ontology terms) are italicized. Covariation patterns are
similar to those determined using microbial abundance (Figure 1).
Additional file 11: KEGG pathways significantly associated with IBD
status or subject metadata using a boosted general linear model.A
multivariate analysis was performed to associate each pathway with a
sparse selection of disease status and clinical metadata (selected through
boosting; see Materials and methods). All pathways and metadata in
these associations are given with nominal P-values from the multivariate
linear model and with Benjamini and Hochberg (BH) corrected false
discovery rate (q-values) up to a threshold of 0.25.
Additional file 12: KEGG metabolic modules significantly associated
with IBD status or subject metadata using a boosted general linear
model. A multivariate analysis was performed to associate each
metabolic module with a sparse selection of disease status and clinical
metadata (selected through boosting; see Materials and methods). Each
module and metadata in these associations is given with nominal p-
values from the multivariate linear model and with Benjamini and
Hochberg (BH) corrected false discovery rate (q-values) up to a threshold
of 0.25.
Additional file 13: Gene Ontology terms significantly associated
with IBD status or subject metadata using a boosted general linear
model. A multivariate analysis was performed to associate each Gene
Ontology term with a sparse selection of disease status and clinical
metadata (selected through boosting; see Materials and methods). Each
term and metadata in these associations is given with nominal P-values
from the multivariate linear model and with Benjamini and Hochberg
(BH) corrected false discovery rate (q-values) up to a threshold of 0.25.
Additional file 14: Shotgun metagenomic sequencing validates
predicted microbial metabolic trends in a subset of healthy and CD
microbiomes. A subset of 11 stool samples for which microbial DNA
was available were subjected to shallow metagenomic sequencing using
the MiSeq platform (150-nucleotide paired-end reads) averaging 119
meganucleotides per sample. (a) Of the seven microbial metabolic
modules highlighted in Figure 5, six retained the same over- or under-
Morgan et al. Genome Biology 2012, 13:R79
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Page 15 of 18abundance trend predicted from 16S sequencing in this subset, with the
seventh (cobalamin biosynthesis) falling below the limit of detection. (b)
Six additional metabolic modules of interest with significant differences
in the full IBD dataset retained the trend expected with CD in this
subset, including depletion of glycolysis processes and enrichment for
bacterial secretion systems.
Additional file 15: Correlation of microbial gene families estimated
from 16S gene pyrosequencing and whole-genome shotgun
sequencing data. Ancestral state reconstruction was used to infer
metagenomes using 16S gene pyrosequencing of samples from multiple
body sites from the Human Microbiome Project (see Materials and
methods). The relative abundance of KOs inferred from 16S sequencing
and measured from paired whole-community genome sequencing
samples were correlated (Spearman rank correlation) and plotted per
body site. Each box plot shows the distribution of the correlation of
relative KO abundance from 16S and whole-genome sequencing; specific
sample-pair correlations are plotted as dots. Median correlation for
Human Microbiome Project stool samples is 0.75 for an average n =7 5
per body site. As each correlation is calculated over approximately 5,400
KOs, correlation values above 0.59 are significant at a Bonferroni-
corrected P < 0.05.
Abbreviations
CD: Crohn’s disease; GG: GreenGenes; GI: gastrointestinal; IBD: inflammatory
bowel disease; iCD: ileal Crohn’s disease; KEGG: Kyoto Encyclopedia of Genes
and Genomes; KO: KEGG ortholog; OSCCAR: Ocean State Crohn’s and Colitis
Area Registry; PRISM: Prospective Registry in IBD Study at MGH; RDP:
Ribosomal Database Project; SCFA: short-chain fatty acid; SFB: segmented
filamentous bacteria; TLR: toll-like receptor; UC: ulcerative colitis.
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